Dishman Carbogen Amcis is planning to raise funds by way of issuance of Non-Convertible Debentures (NCDs), by way of private placement, subject to such regulatory or statutory approvals as may be required. The meeting of the Board of Directors of the company will be held on May 30, 2024, inter alia, to consider, the same.
Dishman Carbogen Amcis (DCAL), incorporated in 1983, started out as a manufacturer of quaternary ammonium and phosphate compounds. Currently, the company is a fully integrated CRAMS player working with global pharmaceutical innovators.